ELOXX PHARMACEUTICALS, INC. Adjustments to Additional Paid in Capital, Other
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Adjustments to Additional Paid in Capital, Other of $285.36 thousand for the 12-month period ending 2017-06-30, per its 10-K filed 2017-10-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2017-10-13
- ELOXX PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for the quarter ending 2017-06-30 was -$22.42K.
- ELOXX PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for the quarter ending 2013-03-31 was -$809.13K, a 500.86% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for the quarter ending 2012-12-31 was $196.57K, a 30.90% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for the quarter ending 2012-09-30 was $153.56K, a 24.29% increase year-over-year.
- ELOXX PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for fiscal 2017 was $285.36K.
- ELOXX PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for fiscal 2012 was $766.00K, a 11.57% decline from fiscal 2011.
- ELOXX PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for fiscal 2011 was $866.24K, a 124.04% increase from fiscal 2010.
- ELOXX PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for fiscal 2010 was $386.64K, a 23.72% decline from fiscal 2009.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$22.42K derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13 | $285.36K 10-K · filed 2017-10-13 | ||
| 2017-03-31 | $307.77K 10-Q · filed 2017-05-22 | |||
| 2013-03-31 | -$809.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-15 | -$612.56K derived: sum of 2 quarters · filed 2013-05-15 | -$459.00K 10-Q · filed 2013-05-15 | -$302.87K derived: sum of 4 quarters · filed 2014-09-29 |
| 2012-12-31 | $196.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-14 | $350.13K 10-Q · filed 2013-02-14 | $506.26K derived: sum of 3 quarters · filed 2014-09-29 | $708.11K derived: sum of 4 quarters · filed 2014-09-29 |
| 2012-09-30 | $153.56K 10-Q · filed 2012-11-14 | $309.69K derived: sum of 2 quarters · filed 2014-09-29 | $511.54K derived: sum of 3 quarters · filed 2014-09-29 | $796.01K derived: sum of 4 quarters · filed 2014-09-29 |
| 2012-06-30 | $156.13K derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29 | $357.98K derived: sum of 2 quarters · filed 2014-09-29 | $642.45K derived: sum of 3 quarters · filed 2014-09-29 | $766.00K 10-K · filed 2014-09-29 |
| 2012-03-31 | $201.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-14 | $486.32K derived: sum of 2 quarters · filed 2012-05-14 | $609.88K 10-Q · filed 2012-05-14 | |
| 2011-12-31 | $284.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-14 | $408.03K 10-Q · filed 2012-02-14 | ||
| 2011-09-30 | $123.55K 10-Q · filed 2011-11-14 | |||
| 2011-06-30 | $866.24K 10-K · filed 2013-09-11 | |||
| 2010-06-30 | $386.64K 10-K · filed 2013-09-11 | |||
| 2009-06-30 | $506.85K 10-K · filed 2013-09-11 | |||
| 2008-06-30 | $1.54M 10-K · filed 2013-09-11 | |||
| 2007-06-30 | $970.16K 10-K · filed 2013-09-11 | |||
| 2006-06-30 | $677.00K 10-K · filed 2013-09-11 | |||
| 2005-06-30 | $974.24K 10-K · filed 2013-09-11 | |||
| 2004-06-30 | $1.83M 10-K · filed 2013-09-11 | |||
| 2003-06-30 | $848.84K 10-K · filed 2013-09-11 | |||
| 2002-06-30 | $1.85M 10-K · filed 2013-09-11 | |||
| 2001-06-30 | $308.62K 10-K · filed 2013-09-11 | |||
| 2000-06-30 | $1.48M 10-K · filed 2013-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |